Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marianne B Treppendahl

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
The Journal of Clinical Investigation|January 3, 2014
Predicting response to epigenetic therapyMarianne B Treppendahl, Lasse S Kristensen, Kirsten Grønbæk
European Journal of Haematology|November 30, 2012
Downregulation but lack of promoter hypermethylation or somatic mutations of the potential tumor suppressor CXXC5 in MDS and AML with deletion 5qMarianne B Treppendahl, Lars Möllgård, Eva Hellström-Lindberg, et al.
Diabetes, Obesity & Metabolism|January 7, 2020
Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular riskMansoor Husain, Stephen C Bain, Ole K Jeppesen, et al.
Oncotarget|April 1, 2015
Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylationAndreas D Ørskov, Marianne B Treppendahl, Anni Skovbo, et al.
Diabetes, Obesity & Metabolism|March 5, 2019
Trial design and baseline data for LIRA-PRIME: A randomized trial investigating the efficacy of liraglutide in controlling glycaemia in type 2 diabetes in a primary care settingJeff Unger, Dale C Allison, Melissa Carlton, et al.
The New England Journal of Medicine|August 25, 2023
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and ObesityMikhail N Kosiborod, Steen Z Abildstrøm, Barry A Borlaug, et al.
The New England Journal of Medicine|April 8, 2024
Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 DiabetesMikhail N Kosiborod, Mark C Petrie, Barry A Borlaug, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
The Journal of Clinical Investigation|January 3, 2014
Predicting response to epigenetic therapyMarianne B Treppendahl, Lasse S Kristensen, Kirsten Grønbæk
European Journal of Haematology|November 30, 2012
Downregulation but lack of promoter hypermethylation or somatic mutations of the potential tumor suppressor CXXC5 in MDS and AML with deletion 5qMarianne B Treppendahl, Lars Möllgård, Eva Hellström-Lindberg, et al.
Diabetes, Obesity & Metabolism|January 7, 2020
Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular riskMansoor Husain, Stephen C Bain, Ole K Jeppesen, et al.
Oncotarget|April 1, 2015
Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylationAndreas D Ørskov, Marianne B Treppendahl, Anni Skovbo, et al.
Diabetes, Obesity & Metabolism|March 5, 2019
Trial design and baseline data for LIRA-PRIME: A randomized trial investigating the efficacy of liraglutide in controlling glycaemia in type 2 diabetes in a primary care settingJeff Unger, Dale C Allison, Melissa Carlton, et al.
The New England Journal of Medicine|August 25, 2023
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and ObesityMikhail N Kosiborod, Steen Z Abildstrøm, Barry A Borlaug, et al.
The New England Journal of Medicine|April 8, 2024
Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 DiabetesMikhail N Kosiborod, Mark C Petrie, Barry A Borlaug, et al.
Pageof 1